5 / 13
Page 21
allied
academies
J Nutr Hum Health 2017 Volume 1 Issue 2
Notes:
July 24-26, 2017 | Vancouver, Canada
International conference on
DIABETES, NUTRITION, METABOLISM & MEDICARE
Aim/Hypothesis:
Ayurvedic formulation "Triphala" had
gained considerationas anantidiabeticmedicine in the Indian
pharmacopeia. Chronic hyperglycemia is often associated
with oxidative stress. To address oxidative stress and the
related aetiologies viz., dyslipidemia and inflammation, we
enhanced the potent antioxidant component E. officinalis
and validated this anti diabetic formulation Triphala-411
viz., (Emblica officinalis: Terminalia chebula: Terminalia
bellarica::4:1:1).
Methods:
Triphala-411 at a dose of 5 grams BD was
administered orally for 12 months to human subjects with
Type 2 diabetes, (n=20), Impaired glucose tolerance, IGT
(n=10) and Normal glucose tolerance, NGT (n=10), based
on their blood glucose levels and OGTT as recommended by
WHO to assess its anti hyperglycemic, anti hyperlipidemic,
anti oxidative and anti inflammatory potentials.
Results:
Significant reduction in blood glucose and
atherogenic lipids in Triphala-411 treated IGT as well as Type
2 diabetes subjects could be attributed to the enhanced
expression of AMP activated protein kinase and decreased
expression of protein kinase C. Anti-inflammatory potential
as assessed through down regulation of Interleukin-6 and
TNF-α, up regulationof Interleukin-10 gene; and antioxidative
effect as assessed through significantly increased activity
of antioxidant enzymes, reduction in lipid peroxidation,
significant reduction in comet tail length and Sub-G1 phase
of cell cycle exhibited resistance to stresses developed
during progression of Type 2 diabetes. Triphala-411 therapy
also addressed diabetic complications as evident from the
down regulation of Aldose reductase and Poly- ADP ribose
polymerase.
Conclusions:
Triphala-411 proved itself as evidence based
alternative anti-diabetic formulation owing to its anti-
hyperglycemic, anti-hyperlipidemic, anti-oxidative and anti-
inflammatory potential.
Biography
Nita Singh has completed her PhD in Biotechnology on identification of cellular
target of Triphala with respect to its antidiabetic and antioxidative potential in
human subjects with Type II diabetes at the age of 33 years from Department of
biotechnology, Jiwaji University, Gwalior and; Pharmacology and toxicology, Defense
research and development establishment, Gwalior, India. She is presently working on
drug development against hepatocellular carcinoma from natural compounds using
insilico approach in All India Institute of Medical Sciences, New Delhi, India. She has
published more than 6 papers in peer reviewed journals.
nitasingh19@gmail.comTriphala improves glucose and lipid homeostasis by targeting AMPK, inflammation and oxidative
stress in human type 2 diabetes
Nita Singh
All India Institute of Medical Sciences, India